Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 12 of 12 for “"aromatase inhibitors"”.
-
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors In Breast Cancer
… hormone receptors and need hormonal therapy. Aromatase inhibitors (AIs) block estrogen biosynthesis and are considered as the first line hormonal therapy for ER<sup>+ </sup>post-menopausal patients. However, resistance to these drugs remains a major challenge in clinic and the biology of such …
-
Symptoms Experienced By Post-Menopausal Breast Cancer Survivors On Aromatase Inhibitors: A Secondary Analysis Of Baseline Data
… Endocrine therapy for breast cancer with Aromatase Inhibitors (AI) is designed to reduce risk of recurrence and improve survival. AI therapy is associated with a variety of symptoms including musculoskeletal complaints, which have contributed to discontinuation of treatment. It is …
-
Development Of Novel Analytical Methods For Detection And Determination Of Tamoxifen In Oral Fluid And Discrimination Between Regioisomeric Aromatase Inhibitors For Doping Control Purposes
… low libido, etc.). Similarly, the use of AIs (Aromatase Inhibitors) has also increased among athletes for identical reasons, and they are also banned by WADA within the same drug classification. This project’s overall goal was to develop and optimize a simple, sensitive and selective method for …
-
Treatment Side Effects & Nonadherence among Women Taking Adjuvant Endocrine Therapy for Breast Cancer: The Role of Psychological Factors
… endocrine therapy with either tamoxifen or aromatase inhibitors significantly increases the risk of breast cancer recurrence. Side effects are a key driver of nonadherence to these treatments. As part of this doctoral research, two studies were conducted to explore the possibility that …
-
Predicting Adherence to Aromatase Inhibitor Therapy in Patients with Breast Cancer Using Protection Motivation Theory
… the psychosocial factors affecting adherence to Aromatase Inhibitors (AI). The aim of this study is to identify and assess the factors affecting adherence to Aromatase Inhibitor Theory in breast cancer patients using the Protection Motivation.Methods: Cross-sectional retrospective study. 288 …
-
Necrotic cell death: A novel outcome of BHPI-hyperactivation of the anticipatory unfolded protein response
… these cancers is endocrine therapy, including aromatase inhibitors and selective estrogen receptor modulators and degraders (SERMs and SERDs), that either block the production of estrogen or competitively inhibit the binding of estrogen to ERa. These small molecule antiestrogens work by …
-
The Role of Androgen Receptor Signalling in Endocrine Resistant Breast Cancer
… patients usually involves endocrine therapies (Aromatase Inhibitors and antioestrogens), which are successful in many patients, but therapy resistance represents a major clinical issue. The Androgen Receptor (AR) is a transcription factor that is more highly expressed than ERα in BCa, and …
-
Cell Cycle Regulatory Roles of Estrogen Receptor Alpha (Erα) In Breast Cancer Cells
… of drugs that lower estrogen level (such as aromatase inhibitors) and preserves ERα from degradation would provide better outcome for breast cancer treatment. We have shown that APC functions as the E3 ligase for ERα and thus might provide a target to design a specific inhibitor of ERα …
-
Tamoxifen metabolites can target both aromatase and estrogen receptors
… estrogen receptor down-regulators (SERDs) and aromatase inhibitors (AIs). However, the efficacy and safety of SERMs, SERDs and AIs are compromised by side effects or tumor resistance. One possible way of improving treatment efficacy and safety profiles is to develop agents with dual aromatase …
-
Tracing Androgen Metabolism With Inhibition Of Aromatase In Breast Cancer: In Vitro Studies And Clinical Correlates
Development of specific inhibitors targeting the enzyme aromatase represents a highly successful example of rational drug design in hormone-responsive cancer. Aromatase inhibitors (AI) are approved as a first line of therapy in both primary and metastatic estrogen-receptor positive (ER+) breast …
-
Spectroscopic characterization of iron-oxygen intermediates in human aromatase (CYP19A1)
CYP19A1 or aromatase, is a human steroidogenic P450 important for estrogen biosynthesis in humans. Over activation of aromatase results in malignancies of the breast tissue, especially in post menopausal women. In fact, aromatase inhibitors constitute the front line therapy for estrogen receptor …